Search clinical trials for: Placebo to ezetimibe/atorvastatin

Total 1497 results

Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

Hypercholesterolemia
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

Hypercholesterolemia
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Hyperlipidemia

Canada, Denmark, France, United States, Czechia, New Zealand, Australia, South Africa, Italy, United Kingdom, Netherlands, Germany, Norway
Boryung Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Essential Hypertension | Primary Hypercholesterolemia

Korea, Republic of
Daewon Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

Hypercholesterolemia, Dyslipidemia

Korea, Republic of
Organon and Co

Completed

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

Hyperlipidemia
Organon and Co

Completed

Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)

Hypercholesterolemia
Organon and Co

Completed

A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)

Hypercholesterolemia
Organon and Co

Completed

To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)

Hypercholesterolemia
Abbott

Completed

A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe

Pharmacokinetics

United States
Organon and Co

Completed

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Hypercholesterolemia
Penza State University

Recruiting

Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19 (CONTRAST-3)

Covid19 | STEMI | NSTEMI

Russian Federation
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

Hyperlipidemia

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
Organon and Co
Merck Shering-Plough JV Study

Completed

A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)

Hypercholesterolemia
Shanghai Jiao Tong University School of Medicine

Unknown

Atorvastatin Plus Ezetimibe on Coronary Plaque Progression (AEPP)

Coronary Artery Disease

China
Abbott

Completed

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Dyslipidemias | Coronary Heart Disease | Mixed Dyslipidemia | Combined (Atherogenic) Dyslipidemia

United States
Organon and Co

Completed

To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)

Hypercholesterolemia
Organon and Co

Completed

Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

Hypercholesterolemia
Abant Izzet Baysal University

Unknown

A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis

Diabetes Mellitus | Hypercholesterolemia | Coronary Heart Disease | Non-Coronary Atherosclerotic Disease

Turkey
Pfizer

Terminated

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Dyslipidemia | Hyperlipidemia

United States
Kumamoto University

Completed

Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS)

Coronary Artery Disease | Hypercholesterolemia

Japan
Organon and Co

Completed

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)

Hypercholesterolemia
Abbott

Completed

A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin

Hyperlipidemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)

Coronary Artery Disease | Atherosclerosis | Hypercholesterolemia
Imperial College London
Regeneron Pharmaceuticals; Baim Institute for Clinical Research

Withdrawn

Early Alirocumab to Reduce LDL-C in Myocardial Infarction (EARLY)

Myocardial Infarction | Dyslipidemias

United Kingdom
Seoul National University Bundang Hospital
Korea United Pharm. Inc.

Recruiting

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Diabetes Mellitus, Type 2 | Atherosclerosis | Dyslipidemias

Korea, Republic of
Organon and Co

Completed

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)

Atherosclerosis | Hypercholesterolemia
Seoul National University Hospital
Merck Sharp & Dohme LLC

Unknown

Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes

Type 2 Diabetes Mellitus Without Insulin Treatment

Korea, Republic of
Organon and Co
PT. Schering-Plough. Tbk Indonesia

Completed

Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)

Hypercholesterolemia | Coronary Arteriosclerosis
Amgen

Completed

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Hyperlipidemia

United States, Denmark, France, Italy, Czechia, Taiwan, Switzerland, Korea, Republic of, Germany, Hong Kong, Netherlands, Australia, Belgium, Canada, Hungary, South Africa, Russian Federation, Spain, United Kingdom, Sweden, Mexico
Organon and Co

Completed

A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)

Hypercholesterolemia
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY EAST)

Hypercholesterolemia

China, India, Thailand
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers

Hypertension | Hypercholesterinemia

Korea, Republic of
Aegerion Pharmaceuticals, Inc.

Completed

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Hyperlipidemia

United States
Yonsei University

Recruiting

Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial

Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation

Korea, Republic of
Organon and Co

Completed

Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)

Familial Hypercholesterolemia
Xijing Hospital

Unknown

Ezetimibe and Atorvastatin Therapy on TCFA

Coronary Artery Disease

China
Organon and Co
Merck Sharp & Dohme LLC

Completed

Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)

Hypercholesterolemia
Organon and Co

Completed

Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Dyslipidemia
Organon and Co
Merck Sharp & Dohme LLC

Terminated

Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)

Coronary Artery Disease | Atherosclerosis | Hypercholesterolemia
Organon and Co

Completed

Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)

Type 2 Diabetes Mellitus | Hypercholesterolemia
Organon and Co

Completed

MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)

Hypercholesterolemia
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Hyperlipidemia

United States, Denmark, Taiwan, Korea, Republic of, Australia, Belgium, Canada, South Africa, France, Turkey
Organon and Co

Completed

Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)

Hypercholesterolemia

3

Subscribe